{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-029394","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.720145+00:00","generated_at":"2026-06-24T00:07:13.544643+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TherapeuticsMD Q2 net income $112.3M; revenue $28.6M (+24% YoY); ANNOVERA sales double","bullets":["Net revenue $28.6M, up 24% YoY; net income $112.3M ($12.83 basic EPS) vs net loss $42.7M in Q2 2021.","ANNOVERA revenue $18.3M, up 91% YoY; 9,329 TRx (+28% YoY); over 13,000 prescribing HCPs (+65%).","Operating expenses fell 21% to $42.7M; debt reduced to $90.8M after repaying $125M in 2022.","Cash $26.3M plus $11.3M restricted; vitaCare divestiture gain $143.4M.","FDA approved sNDA for ANNOVERA; CEO highlights focus on women's health."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-029394","json":"https://secwatch.observer/filing/0001564590-22-029394.json","markdown":"https://secwatch.observer/filing/0001564590-22-029394.md","text":"https://secwatch.observer/filing/0001564590-22-029394.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000156459022029394/0001564590-22-029394-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000156459022029394/txmd-8k_20220815.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:07:13.544643+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}